84.03
0.96 (1.16%)
| 前收盘价格 | 83.07 |
| 收盘价格 | 83.00 |
| 成交量 | 475,496 |
| 平均成交量 (3个月) | 2,444,796 |
| 市值 | 13,610,708,992 |
| 预期市盈率 (P/E Forward) | 90.91 |
| 价格/销量 (P/S) | 13.78 |
| 股市价格/股市净资产 (P/B) | 21.99 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2025 |
| 营业毛利率 | -63.86% |
| 营业利益率 (TTM) | -111.59% |
| 稀释每股收益 (EPS TTM) | -2.99 |
| 季度收入增长率 (YOY) | 10.10% |
| 总债务/股东权益 (D/E MRQ) | 413.80% |
| 流动比率 (MRQ) | 9.66 |
| 营业现金流 (OCF TTM) | -501.78 M |
| 杠杆自由现金流 (LFCF TTM) | -368.16 M |
| 资产报酬率 (ROA TTM) | -10.59% |
| 股东权益报酬率 (ROE TTM) | -118.62% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Ionis Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -3.0 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.50 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.83% |
| 机构持股比例 | 108.17% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tweedy, Browne Co Llc | 31 Dec 2025 | 2,464,930 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 110.00 (HC Wainwright & Co., 30.91%) | 购买 |
| 中 | 98.50 (17.22%) | |
| 低 | 77.00 (Piper Sandler, -8.37%) | 购买 |
| 平均值 | 96.50 (14.84%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 76.11 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wells Fargo | 05 Jan 2026 | 100.00 (19.01%) | 购买 | 78.53 |
| RBC Capital | 17 Dec 2025 | 95.00 (13.05%) | 购买 | 77.08 |
| Leerink Partners | 15 Dec 2025 | 100.00 (19.01%) | 购买 | 79.76 |
| B of A Securities | 09 Dec 2025 | 97.00 (15.43%) | 购买 | 78.86 |
| HC Wainwright & Co. | 10 Nov 2025 | 110.00 (30.91%) | 购买 | 69.54 |
| Piper Sandler | 04 Nov 2025 | 77.00 (-8.37%) | 购买 | 72.88 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| DEVERS SHANNON L. | - | 81.79 | -3,977 | -325,279 |
| 累积净数量 | -3,977 | |||
| 累积净值 ($) | -325,279 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 81.79 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| DEVERS SHANNON L. | 职员 | 22 Jan 2026 | 自动卖出 (-) | 3,977 | 81.79 | 325,279 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合